Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica
Open Access
- 1 April 2022
- journal article
- research article
- Published by Elsevier in Neurología
- Vol. 37 (3) , 178-183
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Safety and Efficacy of Tocilizumab for the Treatment of Rheumatoid ArthritisClinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2012
- Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximabNeurology, 2011
- Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis opticaProceedings of the National Academy of Sciences of the United States of America, 2011
- Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6Multiple Sclerosis Journal, 2010
- Enhanced IL-6 Production in Aquaporin-4 Antibody Positive Neuromyelitis Optica PatientsInternational Journal of Neuroscience, 2010
- Tocilizumab: A Review of Its Safety and Efficacy in Rheumatoid ArthritisClinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2010
- Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosisJournal of Neurology, 2009
- Review: Treatment of neuromyelitis optica: Current debateTherapeutic Advances in Neurological Disorders, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Clinical characteristics, course and prognosis of relapsing Devic?s Neuromyelitis OpticaJournal of Neurology, 2004